Cargando…
6′-Sialyllactose Ameliorates In Vivo and In Vitro Benign Prostatic Hyperplasia by Regulating the E2F1/pRb–AR Pathway
Background: 6′-Sialyllactose (6SL) displays a wide range of the bioactive benefits, such as anti-proliferative and anti-angiogenic activities. However, the therapeutic effects of 6SL on benign prostatic hyperplasia (BPH) remain unknown. Methods: Six-week-old male Wistar rats (n = 40) were used for i...
Autores principales: | Jin, Bo-Ram, Kim, Hyo-Jung, Kim, Eun-Yeong, Chung, Tae-Wook, Ha, Ki-Tae, An, Hyo-Jin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770807/ https://www.ncbi.nlm.nih.gov/pubmed/31547405 http://dx.doi.org/10.3390/nu11092203 |
Ejemplares similares
-
6-sialyllactose ameliorates dihydrotestosterone-induced benign prostatic hyperplasia through suppressing VEGF-mediated angiogenesis
por: Kim, Eun-Yeong, et al.
Publicado: (2019) -
Antioxidant mitoquinone suppresses benign prostatic hyperplasia by regulating the AR–NLRP3 pathway
por: Jin, Bo-Ram, et al.
Publicado: (2023) -
Umbelliferone Ameliorates Benign Prostatic Hyperplasia by Inhibiting Cell Proliferation and G1/S Phase Cell Cycle Progression through Regulation of STAT3/E2F1 Axis
por: Kim, Hyo-Jung, et al.
Publicado: (2021) -
Sialyllactose suppresses angiogenesis by inhibiting VEGFR-2 activation, and tumor progression
por: Chung, Tae-Wook, et al.
Publicado: (2017) -
Relevance of pRB Loss in Human Malignancies
por: Mandigo, Amy C., et al.
Publicado: (2022)